Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology

23-04-2024 | Nephrectomy | Original Article

Short- and long-term post-nephrectomy outcomes for retroperitoneal liposarcoma from a high-volume sarcoma center: a propensity score matching analysis

Authors: Guoqiang Xue, Zhen Wang, Bonan Liu, Chengpeng Li, Ang lv, Xiuyun Tian, Jianhui Wu, Hui Qiu, Chunyi Hao

Published in: International Journal of Clinical Oncology

Login to get access

Abstract

Background

Multivisceral en bloc resection with the ipsilateral kidney is commonly performed in patients with retroperitoneal liposarcoma (RLPS). We evaluated the effect of nephrectomy on short- and long-term outcomes in patients with RLPS.

Methods

Data from a prospectively maintained database of the Peking University Cancer Hospital Sarcoma Center between April 2011 and August 2022 were analyzed. We classified the RLPS patients who underwent surgery into nephrectomy group (NP) and non-nephrectomy group (non-NP). Patients were matched using a 1:1 propensity score to eliminate baseline differences between groups. Postoperative renal function outcomes, major morbidity, and mortality were analyzed to compare short-term outcomes after nephrectomy. Differences in local recurrence-free survival (LRFS) and overall survival (OS) were compared by Kaplan–Meier analysis with respect to oncological benefits.

Results

In the matched cohort, patients in the NP group had significantly higher postoperative eGFR and CKD stages, but none required dialysis. Patients between NP and non-NP had a comparable major morbidity (p = 0.820) and 60-day mortality (p = 0.475). Patients in the NP group had a higher 5‐year LRFS rates than those in the non-NP group (34.5 vs. 17.8%, p = 0.015), and similar 5‐year OS rates (52.4 vs. 47.1%, p = 0.401). Nephrectomy was an independent risk factor for LRFS, but not for major morbidity or OS.

Conclusions

RLPS resection with nephrectomy is related to a mild progression of renal impairment; however, dialysis is rare. En bloc nephrectomy for complete resection of RLPS is safe and improves local control.
Literature
1.
2.
de Bree E, Michelakis D, Heretis I et al (2023) Retroperitoneal soft tissue sarcoma: emerging therapeutic strategies. Cancers (Basel) 15(22):5469CrossRefPubMed
3.
Danieli M, Swallow CJ, Gronchi A (2023) How to treat liposarcomas located in retroperitoneum. Eur J Surg Oncol 49(6):1068–1080CrossRefPubMed
4.
Rust DJ, Kato T, Yoon SS (2022) Treatment for local control of retroperitoneal and pelvis sarcomas: a review of the literature. Surg Oncol 43:101814CrossRefPubMed
5.
Improta L, Tzanis D, Bouhadiba T et al (2020) Overview of primary adult retroperitoneal tumours. Eur J Surg Oncol 46(9):1573–1579CrossRefPubMed
6.
Bonvalot S, Roland C, Raut C et al (2023) Histology-tailored multidisciplinary management of primary retroperitoneal sarcomas. Eur J Surg Oncol 49(6):1061–1067CrossRefPubMed
7.
Improta L, Pasquali S, Iadecola S et al (2023) Organ infiltration and patient risk after multivisceral surgery for primary retroperitoneal liposarcomas. Ann Surg Oncol 30(7):4500–4510CrossRefPubMed
8.
9.
Tirotta F, Bacon A, Collins S et al (2023) Primary retroperitoneal sarcoma: a comparison of survival outcomes in specialist and non-specialist sarcoma centres. Eur J Cancer 188:20–28CrossRefPubMed
10.
Munoz P, Bretcha-Boix P, Artigas V et al (2022) Surgical principles of primary retroperitoneal sarcoma in the era of personalized treatment: a review of the frontline extended surgery. Cancers (Basel) 14(17):4091CrossRefPubMed
11.
Lv A, Liu D-N, Wang Z et al (2023) Short- and long-term surgical outcomes of pancreatic resection for retroperitoneal sarcoma: a long-term single-center experience of 90 cases. J Surg Oncol. 127(4):633–644CrossRefPubMed
12.
13.
Swallow CJ, Strauss DC, Bonvalot S et al (2021) Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the transatlantic Australasian RPS Working Group. Ann Surg Oncol. 28(12):7873–7888CrossRefPubMedPubMedCentral
14.
Kallen ME, Hornick JL (2021) The 2020 WHO classification: what’s new in soft tissue tumor pathology? Am J Surg Pathol 45(1):e1–e23CrossRefPubMed
15.
Neuville A, Chibon F, Coindre J-M (2014) Grading of soft tissue sarcomas: from histological to molecular assessment. Pathology 46(2):113–120CrossRefPubMed
16.
Gronchi A, Miceli R, Colombo C et al (2012) Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Ann Oncol 23(4):1067–1073CrossRefPubMed
17.
Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 240(2):205–213CrossRefPubMedPubMedCentral
18.
Pattaro C, Riegler P, Stifter G et al (2013) Estimating the glomerular filtration rate in the general population using different equations: effects on classification and association. Nephron Clin Pract 123(1–2):102–111CrossRefPubMed
19.
Foundation NK (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 39(2 Suppl 1):210–218
20.
Rodrigues FB, Bruetto RG, Torres US et al (2013) Incidence and mortality of acute kidney injury after myocardial infarction: a comparison between KDIGO and RIFLE criteria. PLoS ONE 8(7):e69998CrossRefPubMedPubMedCentral
21.
Baia M, Ford SJ, Dumitra S et al (2023) Follow-up of patients with retroperitoneal sarcoma. Eur J Surg Oncol 49(6):1125–1132CrossRefPubMed
22.
Hull MA, Niemierko A, Haynes AB et al (2015) Post-operative renal function following nephrectomy as part of en bloc resection of retroperitoneal sarcoma (RPS). J Surg Oncol. 112(1):98CrossRefPubMed
23.
Cho CW, Lee KW, Park H et al (2018) Clinical benefit and residual kidney function of en bloc nephrectomy for perirenal retroperitoneal sarcoma Asia Pac. J Clin Oncol 14(5):e465–e471
24.
Kim DB, Gray R, Li Z et al (2018) Effect of nephrectomy for retroperitoneal sarcoma on post-operative renal function. J Surg Oncol 117(3):425–429CrossRefPubMed
25.
Stahl CC, Schwartz PB, Ethun CG et al (2021) Renal function after retroperitoneal sarcoma resection with nephrectomy: a matched analysis of the United States sarcoma collaborative database. Ann Surg Oncol 28(3):1690–1696CrossRefPubMed
26.
Fairweather M, Lyu H, Conti L et al (2022) Postnephrectomy outcomes following en bloc resection of primary retroperitoneal sarcoma: multicentre study. Br J Surg 109(2):165–168CrossRefPubMed
27.
Tseng WH, Martinez SR, Tamurian RM et al (2011) Contiguous organ resection is safe in patients with retroperitoneal sarcoma: An ACS-NSQIP analysis. J Surg Oncol 103(5):390–394CrossRefPubMed
28.
Wang Z, Wu J, Lv A et al (2018) Infiltration characteristics and influencing factors of retroperitoneal liposarcoma: novel evidence for extended surgery and a tumor grading system. Biosci Trends 12(2):185–192CrossRefPubMed
29.
Fairweather M, Wang J, Jo VY et al (2018) Surgical management of primary retroperitoneal sarcomas: rationale for selective organ resection. Ann Surg Oncol 25(1):98–106CrossRefPubMed
30.
Mussi C, Colombo P, Bertuzzi A et al (2011) Retroperitoneal sarcoma: is it time to change the surgical policy? Ann Surg Oncol 18(8):2136–2142CrossRefPubMed
31.
Anaya DA, Lahat G, Liu J et al (2009) Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg 249(1):137–142CrossRefPubMed
32.
MacNeill AJ, Gronchi A, Miceli R et al (2018) Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the transatlantic RPS working group. Ann Surg 267(5):959–964CrossRefPubMed
33.
Bonvalot S, Miceli R, Berselli M et al (2010) Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol 17(6):1507–1514CrossRefPubMed
34.
Scosyrev E, Messing EM, Sylvester R et al (2014) Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol. 65(2):372–377CrossRefPubMed
Metadata
Title
Short- and long-term post-nephrectomy outcomes for retroperitoneal liposarcoma from a high-volume sarcoma center: a propensity score matching analysis
Authors
Guoqiang Xue
Zhen Wang
Bonan Liu
Chengpeng Li
Ang lv
Xiuyun Tian
Jianhui Wu
Hui Qiu
Chunyi Hao
Publication date
23-04-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-024-02530-2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits